Targets › PDGFR
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2027.
Tyrosine-protein kinase that acts as a cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth…. (UniProt, P09619)
Open in Phaseline: the race on PDGFR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Anlotinib hydrochloride Multi-target tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR inhibitor) | VEGFR, FGFR, PDGFR | Phase 2 | Sarcoma,Soft Tissue | Dec 2027 |
Sarcoma,Soft Tissue (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.